EDGAR·FLOW

Intellia Therapeutics, Inc. — Form 8-K/A

Filed November 13, 2026 · analyzed by the 8-K Agent
8-K/A ▲ Likely positive significance 78/100
What the filing says
Intellia's lonvoguran ziclumeran (lonvo-z), a one-time in vivo CRISPR gene therapy for hereditary angioedema (HAE), achieved its Phase 3 primary endpoint: 62% mean attack-rate reduction weeks 5–28 vs. placebo (p<0.0001), with 87% attack-free weeks (95% CI: 78–93%). The FDA accepted the biologics license application on September 3, 2026, with priority review and a PDUFA goal date of March 10, 2027. Of 93 patients dosed with lonvo-z 50 mg across trials, 100% remain prophylaxis-free with durable effect up to 4 years; 2 Grade 3 serious adverse events occurred (unrelated pulmonary embolism and appendicitis). Intellia has pre-positioned a commercial team, payer outreach (280M+ lives), and authorized treatment center network in anticipation of approval.
Why this rating

First-in-class one-time CRISPR therapy; Phase 3 success and FDA acceptance substantially de-risk near-term approval. Market size ~7,500 treated U.S. HAE patients; ~$641K/year per patient on LTP suggests large revenue opportunity. Represents potential new modality, but HAE is rare; impact material but not transformational relative to ~$870M market cap.

Tradability signal
NO TRADE

No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
before filing · preread
$9.81 ▼ 2.68%
at our read · unknown
$10.08
+10 min · unknown
$10.08 ▲ 0.00%
+30 min · unknown
$10.11 ▲ 0.30%
+1 hr · unknown
$9.88 ▼ 2.03%
+4 hrs · unknown
$9.89 ▼ 1.88%

The stock had already moved +2.75% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ NTLA · stock on Yahoo Finance ↗

See more from November 13, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.